Story excerpt provided by Columbus Business First.
Written by Carrie Ghose.
The Neurotechnology Innovations Translator LLC turned to pharmaceutical experts on both coasts, asking them to evaluate the promise of pain-fighting technology that reduces the need for opioid prescriptions. They both were so excited about it they joined as the startup’s leadership team.
CEO Gregory Fiore and COO Bryan Jones started this month at Sollis Therapeutics Inc., the second company created with seed funding from the public-private commercialization center. Fiore, a non-practicing physician and pharmaceutical consultant who developed drug safety products, is moving to Central Ohio from Boston. Jones is a geneticist who had led cancer pain programs at Sorrento Therapeutics Inc. (NASDAQ:SRNE) in San Diego.
Click here to read the complete article.
Originally published May 3, 2017.